Company / Operating Cash Flow
enGene Holdings Inc. Operating Cash Flow History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$99.2M
FY2025
5-year range
-$99.2M / -$17.6M
FY2022-FY2025
Trend
-105.5%
vs FY2024
Sector context
#126 of 215
Health Care
What the data says
At -$99M, enGene Holdings Inc.'s operating cash flow ranks #126 of 215 in the Health Care sector. Operating Cash Flow has declined for 3 consecutive years, from -$18M in FY2022 to -$99M in FY2025.
Based on SEC 10-K filings.
-$99M in FY2025.
Declined from -$25M to -$99M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#126 of 215 in Health CareTop 59% of 215This company -$99.2M Sector average $661.2M
▼
-115.0% below sector average
Key checks
Key Insights
- enGene Holdings Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2025, operating cash flow decreased 105.5% year-over-year.
- Ranks #126 out of 215 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$99.2M | -105.5% |
| FY2024 | -$48.3M | -95.1% |
| FY2023 | -$24.7M | -40.6% |
| FY2022 | -$17.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026